Nootkatone
(+)-Nootkatone · NKT · Nok · 4 · 4a · 5 · 6 · 7 · 8-hexahydro-6-isopropenyl-4 · 4a-dimethyl-2(3H)-naphthalenone
Last updated
At a glance
Overview
Why Nootkatone Has a Following#
Nootkatone is the sesquiterpene ketone that gives grapefruit its smell, and in the supplement world it occupies a specific lane: a CaMKK2-driven AMPK activator that hits the same metabolic switch as metformin and berberine, but through a different upstream kinase. For physique-focused users — recompers, contest-prep guys running fasted cardio, and longevity-minded looksmaxxers stacking glucose-disposal agents — that mechanism is the entire draw.
The reputation rests on two pillars. First, the Murase 2010 work in Am J Physiol Endocrinol Metab showing nootkatone raises AMPKα1/α2 activity in skeletal muscle and liver, increases the AMP/ATP ratio, drives fatty acid oxidation, and produced a meaningful endurance bump in mice on a high-fat diet. Second, the Wei 2025 Molecules paper in db/db diabetic mice showing parallel AMPK activation and ERK1/2 suppression with normalization of fasting glucose and insulin resistance over 8 weeks. Add the Nrf2/HO-1 induction documented in Park 2023's Parkinson model and the picture is coherent: a lipophilic small molecule that nudges glucose disposal, lipid oxidation, and antioxidant tone without metformin's GI burden or Complex I inhibition.
"Nootkatone increased AMPKα1 and α2 activity in C2C12 myotubes and HepG2 hepatocytes, as well as in skeletal muscle and liver, through a cascade of phosphorylation and increased AMP/ATP ratio, thereby enhancing fat oxidation and endurance." — Murase et al., 2010
It is not a thermogenic, not a stim, and not a fat-burner in the ECA sense — the value is in glucose disposal, lipid oxidation, and fasted-training tolerance, layered alongside berberine or metformin rather than replacing them. The sections below cover documented nootkatone dosage ranges, the recomp and fasted-cardio stacks the community actually runs, CYP3A4 interaction caveats, side effects, and how it compares to the other AMPK levers in the toolkit.
How Nootkatone works
AMPK Activation via the CaMKK2 Axis#
Nootkatone's headline mechanism is activation of AMP-activated protein kinase (AMPK) — the same cellular energy sensor targeted by metformin, berberine, and the act of training itself. AMPK is the master switch that flips a cell from anabolic storage mode (lipogenesis, glycogen synthesis) into catabolic burn mode (fatty acid oxidation, glucose uptake, mitochondrial biogenesis).
What makes nootkatone mechanistically interesting is how it activates AMPK. Metformin works upstream through LKB1 and partial Complex I inhibition. Nootkatone routes through CaMKK2 (calcium/calmodulin-dependent protein kinase kinase 2) instead — pharmacologically blocking CaMKK with STO-609 abolishes the effect, while LKB1-null cells respond just fine. This is why nootkatone stacks cleanly with berberine or metformin rather than competing with them: different upstream kinases, same downstream target.
"Nootkatone increased AMPKα1 and α2 activity in C2C12 myotubes and HepG2 hepatocytes, as well as in skeletal muscle and liver, through a cascade of phosphorylation and increased AMP/ATP ratio, thereby enhancing fat oxidation and endurance." — Murase T. et al., American Journal of Physiology - Endocrinology and Metabolism, 2010
Practical outcome: improved fasted-cardio tolerance, better glucose disposal after carb-heavy meals, and a measurable shift toward fatty acid oxidation at rest. The Murase model also showed a ~21% improvement in swim-to-exhaustion endurance, suggesting the substrate shift is real, not just a biomarker change.
Downstream of AMPK: ACC Phosphorylation and Fat Oxidation#
Once AMPK fires, the cascade is well-characterized. AMPK phosphorylates acetyl-CoA carboxylase (ACC), knocking down malonyl-CoA. Falling malonyl-CoA de-represses CPT-1, the gatekeeper that escorts long-chain fatty acids into the mitochondrion for β-oxidation. Simultaneously, SREBP-1c-driven lipogenesis is suppressed in the liver — less de novo fat synthesis, more fat burned.
PGC-1α and downstream mitochondrial biogenesis markers also climb, which is the slow-build adaptation that makes 8–12 week protocols deliver more than the first week alone.
For the physique-focused user, this is the recomp lever: nootkatone biases the cell toward burning circulating and stored fat rather than parking it, while improving how efficiently glucose is pulled out of the bloodstream and into muscle.
MAPK / ERK Suppression and Inflammatory Tone#
The second mechanistic arm is suppression of ERK1/2 (MAPK1/3) phosphorylation, the inflammatory MAPK branch. This is mechanistically distinct from AMPK and contributes to the anti-inflammatory and insulin-sensitizing effects seen in metabolic-disease models.
"Nootkatone significantly activated AMPK and suppressed ERK1/2 phosphorylation, reducing inflammation, fasting glucose, and insulin resistance in db/db mice over 8 weeks." — Wei J. et al., Molecules, 2025
For lifters running heavy orals, looksmaxxers managing skin inflammation, or anyone whose CRP creeps up on a hard cut, the AMPK + ERK suppression combination is the rationale behind nootkatone's inclusion in on-cycle metabolic-support stacks.
Nrf2 / HO-1 Induction and Oxidative Defense#
Nootkatone activates the Nrf2 transcription factor, the master regulator of endogenous antioxidant defense. Nrf2 nuclear translocation drives expression of HO-1 (heme oxygenase-1) and NQO1 (NAD(P)H quinone dehydrogenase 1) — the same pathway hit by sulforaphane from broccoli sprouts.
"Nootkatone treatment led to increased astrocytic Nrf2 activation, elevated HO-1 and NQO1 expression, suppressed microglial activation, and protection of nigral dopaminergic neurons." — Park JE. et al., Antioxidants (Basel), 2023
This Nrf2 arm matters for two practical reasons. First, hepatic Nrf2 induction is plausibly protective during oral AAS cycles where oxidative stress is the dominant injury mechanism — pairing nootkatone with TUDCA and NAC covers cholestatic, glutathione, and Nrf2 angles simultaneously. Second, the central penetration of nootkatone means the Nrf2 effect extends to brain tissue, which is the basis for its inclusion in longevity-leaning stacks.
Mild Acetylcholinesterase Inhibition#
A secondary, weaker mechanism: nootkatone shows modest acetylcholinesterase (AChE) inhibitory activity, slowing the breakdown of acetylcholine at the synapse.
"Nootkatone displayed moderate acetylcholinesterase inhibitory activity, with an IC50 in the high-micromolar range, suggesting possible utility in cognitive support stacks." — Arya A. et al., Biomolecules, 2021
The IC₅₀ is high-micromolar — well below pharmaceutical AChE inhibitors like donepezil — so this is not a standalone nootropic effect. It does, however, explain why users stacking nootkatone with alpha-GPC or CDP-choline report a subtle cognitive tail beyond what the choline source alone delivers. Subtle, not stimulant-like.
CYP3A4 / CYP2C Interaction — The Grapefruit Caveat#
Nootkatone is a grapefruit-derived sesquiterpene, and the grapefruit family is the textbook example of dietary CYP3A4 modulation.
"Nootkatone, a grapefruit sesquiterpene, is a substrate and weak inhibitor of CYP3A and CYP2C isoforms, with potential for modest drug interaction at higher concentrations." — Bailey DG. et al., Nutrition Journal, 2007
The furanocoumarins (bergamottin, dihydroxybergamottin) are the heavy-hitters in raw grapefruit juice, but isolated nootkatone at supplemental doses contributes its own modest CYP3A/CYP2C inhibition. Practically: anyone stacking nootkatone with narrow-therapeutic-index CYP3A4 substrates — certain statins, calcium-channel blockers, immunosuppressants like cyclosporine or tacrolimus, ergot alkaloids — needs to treat the supplement with the same caution as a glass of grapefruit juice. For most physique-focused users running clean panels and no NTI medications, this is a non-issue; it becomes a real consideration when nootkatone is layered onto polypharmacy.
Protocol
| Level | Dose | Frequency | Notes |
|---|---|---|---|
| Low | 100–200 mg | Twice daily | Documented entry-level range |
| Mid | 400–600 mg | Twice daily | Most commonly studied range |
| High | 800–1000 mg | Twice daily | Administered with a fat-containing meal to support absorption of this highly lipophilic molecule. Split AM/PM, or AM and 60–90 min pre-workout for fasted-cardio protocols. |
Cycle length & outcomes
Documented cycle
8–12 weeks
Plateau after
12 wks
Cycle Notes#
Nootkatone is a non-hormonal AMPK activator, so cycling logic is closer to berberine or metformin than to a peptide or AAS. There's no receptor downregulation to design around, no HPTA to recover, and no PCT. The reason protocols still use 8–12 week blocks is practical: it gives bloodwork a clean before/after window, and hedges against any chronic CYP3A drift at sustained higher doses.
Nootkatone Dosage by Goal#
| Goal | Cycle Length | Daily Dose | Timing |
|---|---|---|---|
| Tolerance assessment / first exposure | 1–2 weeks | 100–200 mg | AM with a fat-containing meal |
| Metabolic / longevity baseline | 8–12 weeks | 400 mg (200 mg × 2) | AM + PM with meals |
| Recomp / lean-bulk AMPK stack | 8–12 weeks | 400–600 mg | AM + PM with meals |
| Cutting / fasted-cardio adjunct | 8–16 weeks | 500–800 mg | AM + 60–90 min pre-cardio |
| On-cycle oral AAS metabolic support | Length of oral block | 500–1000 mg | Split with meals |
| Aggressive recomp / scaled-mechanistic | 8–12 weeks | 800–1000 mg | Split 2–3× with meals |
Doses sit well below the rodent-scaled Murase value (~1.2–1.8 g/day for an 80 kg subject) in most community protocols, mostly for cost and CYP3A4 caution. The 400–600 mg/day band is where subjective reports cluster and where the berberine-style stack math works out.
Loading and Tapering#
No loading phase is required and none is documented. AMPK responds to the standing plasma concentration, not to a saturated tissue pool — once a steady twice-daily rhythm is established, the kinase activation is online within the first dose.
No taper on the back end either. Discontinuation produces no rebound hyperglycemia, no withdrawal, no HPTA artifact. Stopping cleanly at week 12 is the norm.
"Nootkatone increased AMPKα1 and α2 activity in C2C12 myotubes and HepG2 hepatocytes, as well as in skeletal muscle and liver, through a cascade of phosphorylation and increased AMP/ATP ratio, thereby enhancing fat oxidation and endurance." — Murase et al., Am J Physiol Endocrinol Metab (2010)
Onset Timing#
The pharmacology is fast, the phenotype is slow.
- Acute (single dose, 60–90 min): AMPK phosphorylation and ACC inhibition are detectable in animal models within an hour of oral dosing. Subjectively this shows up as slightly better fasted-training tolerance — the cardio that normally feels flat at minute 20 holds at minute 30.
- Week 1–2: Post-meal glucose excursions soften. Users on CGMs (often running nootkatone alongside berberine) report flatter post-prandial curves and modestly lower fasting glucose.
- Week 3–4: The endurance and recomp signal builds. The Murase model showed a +21% swimming time-to-exhaustion at 4 weeks of dietary admixture.
- Week 8–12: This is where the metabolic markers move on bloodwork — HOMA-IR, fasting insulin, triglycerides, and HbA1c if run long enough. The db/db mouse normalization in Wei 2025 was an 8-week readout.
"Nootkatone significantly activated AMPK and suppressed ERK1/2 phosphorylation, reducing inflammation, fasting glucose, and insulin resistance in db/db mice over 8 weeks." — Wei et al., Molecules (2025)
Bloodwork Cadence#
Because the entire value proposition is metabolic, bloodwork is the only honest way to know whether a given protocol is working.
| Timepoint | Panel |
|---|---|
| Baseline (week 0) | Fasting glucose, fasting insulin, HOMA-IR, HbA1c, full lipid panel, ALT/AST |
| Week 6 (if stacked with berberine/metformin) | Fasting glucose, fasting insulin, ALT/AST |
| Week 12 (end of cycle) | Full repeat of baseline panel |
Stacking with exogenous insulin, metformin, or aggressive berberine doses warrants glucose monitoring rather than just a single timepoint — additive AMPK pressure plus a hard cut is the realistic scenario for hypoglycemic dips.
Cycle-Off Window#
Four weeks off between 12-week blocks is the conventional community pattern, borrowed wholesale from berberine and metformin protocols. There's no mechanistic argument for this — AMPK is not desensitization-prone — but it gives the hepatic CYP3A4/2C system a clean reset and produces a useful washout for re-baselining bloodwork before the next block.
Indefinite use at 200–400 mg/day for general metabolic-health and longevity stacking has no documented ceiling. The 8–12 week framing exists because that's the window where the published animal endpoints landed, not because the molecule stops working at week 13.
Body Transformation Preview
Lean Mass Gain
0.0 lbs
0.0–0.0 lbs range
Fat Loss
1.6 lbs
1.2–2.0 lbs range
Fat Loss by Week
Risks & mistakes
Common (most users)#
- Mild GI discomfort — occasional nausea, reflux, or grapefruit-pith aftertaste, almost exclusively at single doses ≥500 mg on an empty stomach. Splitting the daily total into 2–3 administrations with a fat-containing meal eliminates this in virtually all subjects.
- Transient post-dose warmth or flushing — a benign vasodilatory response some users notice in the first 30–60 minutes. Resolves within 1–2 weeks of consistent administration; no dose adjustment needed.
- Subjective appetite suppression around meals — a downstream consequence of AMPK activation and improved post-prandial glucose handling. Helpful in a cut, occasionally inconvenient on a lean-bulk; shift the PM dose to pre-workout rather than pre-dinner if it interferes with intake.
- Looser stools on initiation — primarily in users stacking nootkatone with berberine or metformin. Spacing the two compounds by ~2 hours, or dropping the berberine dose by one capsule, resolves it.
Uncommon (dose-dependent or individual)#
- Mild hypoglycemia symptoms — light-headedness, shakiness, or hunger spikes during fasted cardio or prolonged training windows. Most often seen at 800–1000 mg/day or when stacked with berberine, dihydroberberine, metformin, or exogenous insulin. The mitigation is straightforward: fingerstick glucose monitoring during the first two weeks of a new stack, and a small intra-workout carb source (10–20 g) on fasted-cardio days.
- Modest LDL or lipid drift in either direction — AMPK activators occasionally produce small lipid shifts that are not always predictable in direction. A baseline and 12-week lipid panel catches this; citrus bergamot 1 g/day is the standard community lever to nudge it back.
- Mild headache or "fuzzy" feeling at high single doses — typically resolved by switching from a 1×1000 mg dose to 2×500 mg with meals.
- CYP3A4 / CYP2C-mediated interactions — at sustained doses ≥600 mg/day, nootkatone behaves like a weak grapefruit-juice analog. Subjects on statins, calcium-channel blockers, certain benzodiazepines, sildenafil/tadalafil at the high end, or any CYP3A4 substrate should expect modestly elevated plasma levels of the co-administered drug and dose conservatively.
"Nootkatone, a grapefruit sesquiterpene, is a substrate and weak inhibitor of CYP3A and CYP2C isoforms, with potential for modest drug interaction at higher concentrations." — Bailey DG et al., Nutrition Journal (2007)
- Theoretical estradiol drift in TRT / AAS users — anecdotal only. Grapefruit-derivative loads in general can alter steroid clearance via CYP3A. If E2 trends up after starting nootkatone, the resolution is the same as any other E2 management problem: bloodwork, then dose or AI adjustment.
Rare but serious#
- Clinically significant drug-drug interactions with narrow-therapeutic-index CYP3A4 substrates — cyclosporine, tacrolimus, certain anti-arrhythmics (amiodarone, dronedarone), ergot alkaloids, and select oral oncology agents. Plasma-level excursions in this category can be dangerous. Discontinue nootkatone if any of these are introduced and not previously dose-adjusted for grapefruit-class exposure.
- Severe hypoglycemia — only documented when AMPK activators are layered aggressively (nootkatone + berberine + metformin + insulin or sulfonylurea) in a deep fasted state. Warning signs are sweating, tremor, confusion, blurred vision. Stop the stack, get glucose, and rebuild dosing from the bottom.
- Allergic / hypersensitivity reactions to citrus terpenes — rare, predictable in subjects with known citrus terpene or limonene sensitivity. Rash, pruritus, or oral mucosal irritation are the typical presentations. Discontinue.
No hepatotoxicity, no androgen suppression, no HPTA disruption, no hair-loss signal, and no cardiotoxicity has been documented in the published literature.
Hard contraindications#
- Concomitant use with narrow-therapeutic-index CYP3A4 substrates (cyclosporine, tacrolimus, ergot alkaloids, amiodarone, dronedarone, certain protease inhibitors and oral oncology agents). Do not stack.
- Pregnancy and lactation — no safety data exist. Default avoid.
- Known citrus terpene or limonene hypersensitivity.
- Active sulfonylurea or insulin therapy without glucose monitoring — the additive hypoglycemic potential is real and should not be assumed away.
Gender, fertility, and PCT considerations#
Nootkatone is non-hormonal. Dosing is bodyweight-scaled rather than sex-specific, and there is no virilization risk, no menstrual-cycle disruption signal, and no documented effect on semen parameters or testicular function. No PCT is required at any documented dose. Women in the looksmaxxing / recomp audience can run identical protocols to men at proportionally lower total doses (typically 200–400 mg/day). Pregnancy and lactation remain a default-avoid category purely on absence of data, not on any positive signal of harm.
FAQ — Nootkatone
Research & citations
5 studies cited on this page.
Conclusion
Nootkatone stands out as a next-gen AMPK activator for recomp, fasted-cardio, and longevity stacks — with a lean side-effect profile and synergy with other metabolic modulators.
Key takeaways:
- Typical protocol: 200–300 mg orally, twice daily with fat-containing meals (total 400–600 mg/day)
- Cycle duration: 8–12 weeks is standard, with 4+ weeks off if running consecutive blocks
- Headline effect: increased skeletal muscle and liver AMPK activation for improved fat oxidation, metabolic health, and modest endurance boost
"Nootkatone increased AMPKα1 and α2 activity in C2C12 myotubes and HepG2 hepatocytes, as well as in skeletal muscle and liver, thereby enhancing fat oxidation and endurance." — Murase et al., 2010
- Stacks well with berberine or low-dose metformin (targeting complementary AMPK activation pathways) and liver support (TUDCA, NAC) during oral cycles
- Watch for mild CYP3A4/CYP2C9 drug interactions at higher doses; glucose monitoring recommended when stacking multiple insulin sensitizers
- Safe for most non-pregnant users; no PCT, suppression, or hair-loss risk
For users looking to nudge body composition, endurance, and metabolic health, nootkatone offers a well-tolerated and mechanistically reliable addition to an AMPK-focused protocol.